安罗替尼联合瑞戈非尼对结直肠癌患者血管增生、免疫功能及生活质量的影响  

Effect of anlotinib combined with regorafenib on angiogenesis,immune function and quality of life in patients with colorectal cancer

作　　者：贾宇娇 李金龙 王媛[3] JIA Yujiao;LI Jinlong;WANG Yuan(Department of Clinical Medicine,Southern Medical University,Guangzhou 510515,Guangdong,China;Department of Chinese Medicine,Inner Mongolia Medical University,Hohhot 010107,Inner Mongolia,China;Department of Oncology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,Guangdong,China)

机构地区：[1]南方医科大学临床医学系,广州510515 [2]内蒙古医科大学中医学系,呼和浩特010107 [3]南方医科大学南方医院肿瘤科,广州510515

出　　处：《癌症进展》2025年第6期643-647,668,共6页Oncology Progress

摘　　要：目的探讨安罗替尼联合瑞戈非尼对结直肠癌(CRC)患者血管增生、免疫功能及生活质量的影响。方法采用随机数字表法将108例CRC患者分为对照组和联合组,每组45例,对照组患者给予瑞戈非尼治疗,联合组患者在对照组的基础上给予安罗替尼治疗。比较两组患者的疾病控制率、肿瘤标志物[糖类抗原19-9(CA19-9)、大肠特异性抗原-2(CCSA-2)、癌胚抗原(CEA)]水平、血管增生指标[血管内皮生长因子(VEGF)、转化生长因子-β(TGF-β)]、免疫功能指标[CD4^(+)、CD4^(+)/CD8^(+)、程序性死亡受体1(PD-1)、程序性死亡受体配体1(PDL1)]、生活质量[结直肠癌专用生活质量量表(QLQ-CR38)]及复发率。结果联合组患者的疾病控制率为95.56%,高于对照组患者的71.11%,差异有统计学意义(P﹤0.05)。治疗后,两组患者VEGF、TGF-β水平均低于本组治疗前,联合组患者VEGF、TGF-β水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD4^(+)、CD4^(+)/CD8^(+)均高于本组治疗前,PD-1、PD-L1均低于本组治疗前,联合组患者CD4^(+)、CD4^(+)/CD8^(+)均高于对照组,PD-1、PD-L1均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者心理情绪、社会功能、自身形象及肠道功能恢复评分均低于本组治疗前,联合组患者心理情绪、社会功能、自身形象及肠道功能恢复评分均低于对照组,差异均有统计学意义(P﹤0.05)。随访3个月,联合组患者的复发率低于对照组,差异有统计学意义(P﹤0.05)。结论安罗替尼联合瑞戈非尼治疗CRC患者可有效控制疾病进展,抑制血管增生,且可提高患者的免疫功能及生活质量。Objective To investigate the effect of anlotinib combined with regorafenib on angiogenesis,immune function and quality of life in patients with colorectal cancer(CRC).Method A total of 108 CRC patients were divided into control group and combined group by random number table method,with 45 cases in each group.Patients in the control group were given regorafenib treatment,and patients in the combined group were given anlotinib treatment on the basis of the control group.The disease control rate,tumor markers[carbohydrate antigen 19-9(CA19-9),colon cancer-specific antigen-2(CCSA-2),carcinoembryonic antigen(CEA)]levels,vascular proliferation indicators[vascular endothelial growth factor(VEGF),transforming growth faction-β(TGF-β)],and immune function indicators[CD4^(+),CD4^(+)/CD8^(+),programmed cell death 1(PD-1),programmed cell death 1 ligand 1(PD-L1)],quality of life[colorectal cancer-specific quality of life questionnaire module(QLQ-CR38)]and recurrence rate were compared between the two groups.Result The disease control rate of the combined group was 95.56%,which was higher than 71.11%of the control group,the difference was statistically significant(P<0.05).After treatment,the VEGF and TGF-βlevels in both groups were lower than those before treatment,and the VEGF and TGF-βlevels in combined group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,the CD4^(+)and CD4^(+)/CD8^(+)in both groups were higher than those before treatment,the PD-1 and PD-L1 were lower than those before treatment,the CD4^(+)and CD4^(+)/CD8^(+)in combined group were higher than those in control group,and the PD-1 and PD-L1 were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,the scores of psychological emotion,social function,self-image and intestinal function recovery in both groups were lower than those before treatment,and the scores of psychological emotion,social function,self-image and intestinal function recovery i

关 键 词：安罗替尼 瑞戈非尼 结直肠癌 血管增生 免疫功能 

分 类 号：R735.3[医药卫生—肿瘤]